The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The effectiveness of dilanubicel at improving outcomes of single cord blood transplantation
Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the effectiveness of dilanubicel, a non-human leukocyte antigen (HLA)-matched pooled universal product, at improving outcomes of single cord blood transplantation. Dr Milano reports findings from a study showing that all 19 patients treated with dilanubicel engrafted quickly and remained disease-free at a median follow-up of one year, with no severe acute or chronic graft-versus-host disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in this study we investigated the use of dilanubicel, which is a pool-derived cord blood product expanded and ready to be used as an off-the-shelf product for patients undergoing cord blood transplantation with hematological malignancies. We treated 15 patients but we are reporting on 19 at this conference. The main findings of the studies were that all patients engrafted at a median time of 22 days for neutrophils and then grafted also for platelets at a median of 31 days...
So in this study we investigated the use of dilanubicel, which is a pool-derived cord blood product expanded and ready to be used as an off-the-shelf product for patients undergoing cord blood transplantation with hematological malignancies. We treated 15 patients but we are reporting on 19 at this conference. The main findings of the studies were that all patients engrafted at a median time of 22 days for neutrophils and then grafted also for platelets at a median of 31 days. The main finding of the study is that all patients were alive and disease-free at a median follow-up of one year. None of the patients developed grade three and four acute GvHD and none of the patients developed chronic graft-versus-host disease. These results are pretty outstanding considering that we did not lose any patient and that definitely we can export this type of technology and methodology of doing transplantation to many patients receiving a single cord blood transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
